Oral β-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice

Folia Histochemica et Cytobiologica

Volumn 45, Issue 2, 2007, Pages 107-114

  Baran, Jarek ^a,b   Allendorf, Daniel J ^a   Hong, Feng ^a   Ross, Gordon D ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Beta glucan; Intracellular cytokines; Lymphocyte subsets; Macrophages; Th1 and Th2 type response

Indexed keywords

BETA 1,3 GLUCAN; CANCER ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11C1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; IMMUNOREGULATION; MONOTHERAPY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PERITONEUM MACROPHAGE; PROTEIN DETERMINATION; TH1 CELL; TH2 CELL;

MUS;

EID: 34250620982     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Abel G, Czop JK. Stimulation of human monocyte beta-glucan receptors by glucan particles induces production of TNF-alpha and IL-1 beta. Int J Immunopharmacol, 1992; 14: 1363-1373
2. Adachi Y, Okazaki M, Ohno N, Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1→3)-beta-D-glucan, grifolan (GRN), isolated from Grifola frondosa. Biol Pharm Bull, 1994; 17: 1554-1560
3. Bohn JA, BeMiller JN. (1-3)-β-D-glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Polymers, 1995; 28: 3-14
4. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature, 2001; 413: 36-37
5. Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 197: 1119-1124
6. Cheung NK, Modak S, Vickers A, Knuckles B Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother, 2003; 51: 557-564
7. Cheung NK, Modak S. Oral (1→3),(1→4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res, 2002; 8: 1217-1223
8. Chihara G. Preclinical evaluation of lentinan in animal models. Adv Exp Med Biol, 1983; 166: 189-197
9. Chihara G, Hamuro J, Maeda YY et al. Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: an overview. Cancer Detect Prey, 1987; Suppl 1: 423-443
10. Czop JK. The role of beta-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol Immunopathol Res, 1986; 5: 286-296
11. Di Luzio NR, McNamee R, Jones E, Cook JA, Hoffman EO. The employment of glucan and glucan activated macrophages in the enhancement of host resistance to malignancies in experimental animals. In: The macrophage in neoplasia. Fink MA [Ed], Academic Press, New York, 1976; pp 181-198
12. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med, 2003; 197: 1107-1117
13. Hamuro I, Chihara G. Lentinan, a T-cell oriented immunopotentiator. In: Immune modulation agents and their mechanisms. Fenichel RL, Chirigos MA [Eds], Marcel Dekker, New York, 1984; pp 409-436
14. Hashimoto K, Suzuki I, Yadomae T. Oral administration of SSG, a beta-glucan obtained from Sclerotinia sclerotiorum, affects the function of Peyer's patch cells. Int J Immunopharmacol, 1991; 13: 437-442
15. Herre J, Marshall AS, Caron E, Edwards AD, Williams DL, Schweighoffer E, Tybulewicz V, Reis e Sousa C, Gordon S, Brown GD. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood, 2004; 104: 4038-4045
16. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killing cells. Cancer Res, 2003; 63: 9023-9031
17. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Cheung N-KV, Ross GD. Mechanism by which orally administered β-glucans enhance the activity of anti-tumor antibodies. J Immunol, 2004; 173: 797-806
18. Jamas S, Rha CK, Sinskey J. Glucan compositions and process for preparation thereof. US Patent 4810646, 1989
19. Janusz MJ, Austen KF, Czop JK. Lysosomal enzyme release from human monocytes by particulate activators is mediated by beta-glucan inhibitable receptors. J Immunol, 1987; 138: 3897-390l
20. Kraus J, Franz G. Immunomodulating effects of polysaccharides from medicinal plants. Adv Exp Med Biol, 1992; 319: 299-308
21. Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, Yan J. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Sykphosphatidylinositol 3-kinase pathway. J Immunol, 2006; 177: 1661-1669
22. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol, 1996; 156: 73-78
23. Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-D-beta-glucan. Leukocyte Res, 2005; 29: 679-683
24. Morikawa K, Takeda R, Yamazaki M, Mizuno D. Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear beta-l,3-D-glucan and other immunomodulators in murine cells. Cancer Res, 1985; 45: 1496-1501
25. Murata Y, Shimamura T, Tagami T, Takatsuki F, Hamuro J. The skewing to Th1 induced by lentinan is directed through the distinctive cytokine production by macrophages with elevated intracellular glutathione content. Int Immunopharmacol, 2002; 2: 673-689
26. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother, 1996; 42: 1-8
27. Rice PJ, Adams EL, Ozment-Skelton T, Gonzales AJ, Goldman MP, Lokhart BE, Barker LA, Breuel KF, Deponti WK, Kalbfleisch JH, Ensley HE, Brown GD, Gordon S, Williams DL. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther, 2005; 314: 1079-1086
28. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology, 1999; 42: 61-74
29. Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E, Germann T. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol, 1994; 24: 793-798
30. Suzuki I, Tanaka H, Kinoshita A, Oikawa S, Osawa M, Yadomae T. Effect of orally administered beta-glucan on macrophage function in mice. Int J Immunopharmacol, 1990; 12: 675-684
31. Suzuki M, Arika T, Amemiya K, Fujiwara M. Cooperative role of T lymphocytes and macrophages in anti-tumor activity of mice pretreated with schizophyllan (SPG). Jpn J Exp Med, 1982; 52: 59-65
32. Suzuki M, Kikuchi T, Takatsuki F, Hamuro J. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CDS-positive T cells. Cancer Immunol Immunother, 1994; 38: 1-8
33. Suzuki M, Iwashiro M, Takatsuki F, Kuribayashi K, Hamuro J. Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor. Jpn J Cancer Res, 1994; 85: 409-417
34. Suzuki Y, Adachi Y, Ohno N, Yadomae T. Th1/Th2-Balancing immunomodulating activity of gel-forming (1→3)-beta-glucans from fungi. Biol Pharm Bull, 2001; 24: 811-819
35. Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg, 1999; 177: 203-208
36. Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Ogawa N. Clinical efficacy of lentinan on neoplastic diseases. Adv Exp Med Biol, 1983; 166: 181-187
37. Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomarez L, Gordon S, Wong SY. The beta-glucan receptor, dectin- 1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol, 2002; 169: 3876-3882
38. Tsukada C, Yokoyama H, Miyaji C, Ishimoto Y, Kawamura H, Abo T. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell Immunol, 2003; 221: 1-5
39. Tzianabos AO. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev, 2000; 13: 523-533
40. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD 11b/CD 18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest, 1996; 98: 50-61
41. Vetvicka V, Yvin JC. Effects of marine beta-l,3 glucan on immune reactions. Int Immunopharmacol, 2004; 4: 721-730
42. Wakshull E, Brunke-Reese D, Lindermuth J, Fisette L, Nathans RS, Crowley JJ, Tufts JC, Zimmerman J, Mackin W, Adams DS. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology, 1999; 1: 89-107
43. Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, Gordon S, Brown GD. The human beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur J Immunol, 2005; 35: 1539-1547
44. Wu D, Han SN, Bronson RT, Smith DE, Meydani SN. Dietary supplementation with mushroom-derived protein-bound glucan does not enhance immune function in young and old mice. J Nutr, 1998; 128: 193-197
45. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol, 1999; 162: 2281-2290
46. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol, 1999; 163: 3045-3052
47. Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Pathol, 1991; 138: 1437-1450
48. Yoshino S, Tabata T, Hazama S, Iizuka N, Yamamoto K, Hirayama M, Tangoku A, Oka M. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res, 2000; 20: 4707-4711